Berlin-based AI startup sci2sci has raised €1.2 million in pre-seed funding to develop infrastructure designed to make AI more reliable and traceable in regulated industries. The funding comes as European businesses face growing pressure to adopt AI while maintaining high standards around accuracy, compliance and accountability.
The round was co-led by Heliad and IBB Ventures, with participation from Robin Capital and Superangels. Founded by Angelina Lesnikova and Valerii Kremnev, sci2sci is initially focusing on biopharma, an industry where companies work with large volumes of complex scientific and regulatory information.
For organisations operating in highly regulated environments, simply generating an answer with AI is not enough. Teams also need to understand where the information came from, whether the underlying evidence is reliable and how a conclusion was reached.
This is the problem sci2sci is attempting to address. The company is developing infrastructure that connects fragmented enterprise data and creates a more traceable foundation for AI-powered workflows.
Its technology includes VectorCat, which is designed to connect and organise information across existing data sources, and Integrity Cortex, which focuses on linking AI-generated claims back to supporting evidence.
The approach is particularly relevant to biopharma, where information can be distributed across research documents, laboratory systems, regulatory files and other enterprise databases. Bringing those sources together can make it easier for teams to access information without requiring every organisation to completely restructure its existing data infrastructure.
sci2sci’s focus also reflects a broader shift in enterprise AI. As companies move beyond experimentation and begin deploying AI in business-critical processes, concerns around hallucinations, data provenance and explainability are becoming increasingly important.
The company plans to use its new funding to expand its engineering capabilities, deepen customer deployments and grow its presence within the biopharma sector. It also intends to explore additional regulated industries, including banking. That expansion could give sci2sci a wider addressable market across Europe, where regulated businesses are navigating both rapid AI adoption and increasingly demanding expectations around governance and transparency.
Rather than competing purely on the ability to generate AI outputs, sci2sci is building around a different requirement: making those outputs easier to verify and trust. For regulated industries, that distinction could become increasingly important as AI moves deeper into operational and decision-making processes.
Discover more funding news from across Europe.
